Side-by-side comparison of AI visibility scores, market position, and capabilities
Pawtucket RI toys and games (NASDAQ: HAS) at $4.136B FY2024 revenue (-17% post-eOne divestiture); record 20.3% operating margins, $847M operating cash flow, Magic: The Gathering + Monopoly + Transformers competing with Mattel.
Hasbro, Inc. is a Pawtucket, Rhode Island-based global play and entertainment company — publicly traded on NASDAQ (NASDAQ: HAS) as an S&P 500 Consumer Discretionary component — designing, manufacturing, and marketing branded toys, games, licensed products, and tabletop gaming experiences under iconic brands including My Little Pony, Transformers, G.I. Joe, Play-Doh, Peppa Pig, Dungeons & Dragons, Magic: The Gathering, Monopoly, Scrabble, Risk, Trivial Pursuit, and Battleship through approximately 6,000 employees worldwide. In fiscal year 2024, Hasbro delivered record adjusted operating profit of $839 million and record operating margins of 20.3%, while revenue declined 17% to $4.136 billion — reflecting the planned reduction following the completion of the Entertainment One (eOne) film and television production business divestiture (sold to Lionsgate Entertainment in 2023 for $500 million, unwinding the $4.6 billion eOne acquisition of 2019). Excluding the eOne impact, core Consumer Products (toys, games, and licensed products) and Wizards of the Coast (tabletop games, including Magic: The Gathering and Dungeons & Dragons) segments demonstrated improved profitability. The company generated $847 million in operating cash flow, paid $390 million in dividends, reduced debt by $83 million, and achieved $370 million in gross cost savings — reflecting CEO Chris Cocks' "Hasbro Simplified" portfolio restructuring strategy that focuses the company on its highest-returning brands and digital gaming opportunities. Magic: The Gathering remains one of the most valuable entertainment franchises globally, with 40+ million players and digital extensions (Magic: The Gathering Arena) that provide recurring digital revenue.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.